Inge M. Svane
Expertise in
5
conditions

Inge M. Svane

Herlev, DK 
Expertise in
5
conditions
Herlev, DK 

Overview

Inge Svane practices practicing medicine in Herlev, Denmark.

Ms. Svane is highly rated in 5 conditions, according to our data. Her clinical expertise encompasses Melanoma, Metastatic Uveal Melanoma, Melanoma of the Eye, and Myeloproliferative Neoplasms (MPN).

She is actively involved in clinical research, co-authoring 271 peer reviewed articles and participating in 5 clinical trials.

Gender

Female

Locations

Herlev, Denmark
Other Locations
Copenhagen, Denmark
Gentofte, 2900, Denmark
Hellerup, 2900, Denmark

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

A Phase 1, Open-Label, Dose-Escalation Clinical Trial of Tumor Necrosis Factor Alpha and Interleukin 2 Coding Oncolytic Adenovirus TILT-123 in Melanoma Patients Receiving Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes
A Phase 1, Open-Label, Dose-Escalation Clinical Trial of Tumor Necrosis Factor Alpha and Interleukin 2 Coding Oncolytic Adenovirus TILT-123 in Melanoma Patients Receiving Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes
Enrollment Status: Completed
Publish Date: August 07, 2025
Intervention Type: Biological
Study Drug: TILT-123
Study Phase: Phase 1
Randomized Phase III Study Comparing a Non-myeloablative Lymphocyte Depleting Regimen of Chemotherapy Followed by Infusion of Tumor Infiltrating Lymphocytes and Interleukin-2 to Standard Ipilimumab Treatment in Metastatic Melanoma
Randomized Phase III Study Comparing a Non-myeloablative Lymphocyte Depleting Regimen of Chemotherapy Followed by Infusion of Tumor Infiltrating Lymphocytes and Interleukin-2 to Standard Ipilimumab Treatment in Metastatic Melanoma
Enrollment Status: Completed
Publish Date: March 10, 2025
Intervention Type: Drug, Procedure
Study Drugs: Cyclophosphamide, Fludarabine, Interleukin-2, Ipilimumab infusion
Study Phase: Phase 3
A Phase Ib/II Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 in Combination With Durvalumab (MEDI4736) or Tremelimumab or the Combination of Durvalumab and Tremelimumab Compared to IMCgp100 Alone in Patients With Advanced Melanoma
A Phase Ib/II Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 in Combination With Durvalumab (MEDI4736) or Tremelimumab or the Combination of Durvalumab and Tremelimumab Compared to IMCgp100 Alone in Patients With Advanced Melanoma
Enrollment Status: Withdrawn
Publish Date: July 24, 2024
Intervention Type: Drug
Study Drugs: IMCgp100, Durvalumab, Tremelimumab
Study Phase: Phase 1/Phase 2
Adjuvant Pegylated-Interferon-alpha2b (SylatronTM) for 2 Years Versus Observation in Patients With an Ulcerated Primary Cutaneous Melanoma With T(2-4)bN0M0: a Randomized Phase III Trial of the EORTC Melanoma Group.
Adjuvant Pegylated-Interferon-alpha2b (SylatronTM) for 2 Years Versus Observation in Patients With an Ulcerated Primary Cutaneous Melanoma With T(2-4)bN0M0: a Randomized Phase III Trial of the EORTC Melanoma Group.
Enrollment Status: Unknown
Publish Date: March 04, 2019
Intervention Type: Biological
Study Drug: PEG IFN Alfa-2b
Study Phase: Phase 3
Phase II Study of the Tumor-targeting Human F16IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Paclitaxel in Patients With Metastatic Merkel Cell Carcinoma
Phase II Study of the Tumor-targeting Human F16IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Paclitaxel in Patients With Metastatic Merkel Cell Carcinoma
Enrollment Status: Terminated
Publish Date: May 18, 2018
Intervention Type: Drug
Study Phase: Phase 2
View 4 Less Clinical Trials

271 Total Publications

Immune-cytokine signature predicts survival in patients with advanced melanoma treated with oncolytic adenovirus TILT-123 and chemotherapy and IL-2-free adoptive TIL therapy.
Immune-cytokine signature predicts survival in patients with advanced melanoma treated with oncolytic adenovirus TILT-123 and chemotherapy and IL-2-free adoptive TIL therapy.
Journal: Journal for immunotherapy of cancer
Published: July 27, 2026

Frequently Asked Questions about Inge M. Svane

Is Inge M. Svane a top-rated expert for Melanoma?

MediFind is an objective health platform that identifies experts based on real-world data. Inge M. Svane is classified as an Elite expert for Melanoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Inge M. Svane participate in research or clinical trials?

Yes. Inge M. Svane has published 271 articles and abstracts on conditions like Melanoma. You can view a list of Inge M. Svane's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Svane's expertise for a condition
ConditionClose
    View All 24 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile